Life sciences company focusing on novel drug development and pharmaceutical MYND Life Sciences Inc. (OTCMKTS: MYNDF) announced that its wholly owned subsidiary MYND Diagnostics has started a clinical research of an evaluation procedure for diagnosing and monitoring Alzheimer’s Disease.
This clinical research will be utilizing the company’s anti-inflammatory peptide (MAP). MYND’s chief executive officer, Dr. Lyle Oberg says that the researchers have already commenced study and exploration of potential application of the company’s proprietary MAP biomarker for use in the identification of Alzheimer’s disease.
“The ability to make an early, accurate, dependable diagnosis in Alzheimer’s disease patients thereby allowing for earlier intervention is a huge step forward in the fight against this terrible disease. We are extremely excited that the MAP biomarker has the potential to bridge that gap. The Company’s ultimate goal specific to diagnostics is to provide a cost-effective, easy to use diagnostic test kit that can be administered from anywhere with a dried blood spot. Helping families and health care practitioners with an effective tool for early diagnosis, monitoring and treatment for the millions impacted by this disease will be a significant innovation in central nervous system medicine,” said the CEO.
Citing recorded data, around 44 million people live with Alzheimer’s disease or a related form of dementia across the world. In the United States, Alzheimer’s disease is the sixth leading cause of death which means it kills more people than prostate and breast cancer combined.
The company is aiming at developing diagnostic test to monitor and diagnose inflammatory diseases of the central nervous system like Alzheimer’s disease. This diagnostic test is seeking give heath care workers an objective monitoring tool to advance patient outcomes by providing more tailor made and effective treatments.
